Why dyspepsia can occur without organic disease: Pathogenesis and management of functional dyspepsia

Journal of Gastroenterology

Volumn 47, Issue 8, 2012, Pages 862-871

  Miwa, Hiroto ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Abnormal gastric motility; Dyspepsia; Functional gastrointestinal disorders; Stress; Visceral hypersensitivity

Indexed keywords

ACOTIAMIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; KAMPO; LANSOPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; DIET; DRUG EFFECT; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; ERADICATION THERAPY; EXERCISE; GASTROENTERITIS; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HEREDITY; HUMAN; HYPNOSIS; LIFESTYLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STOMACH ACID SECRETION; STOMACH MOTILITY; SYMPTOM;

DYSPEPSIA; HUMANS;

EID: 84867572981     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0625-9     Document Type: Review

References (100)

1. Colin-Jones D, Bloom B, Bodemar G, Crean G, Freston J, Gugler R, et al. Management of dyspepsia: report of a working party. Lancet. 1988;331:576-9.
2. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466-79.
3. Talley N, Colin-Jones D, Koch K. Functional dyspepsia. A classification with guidelines for diagnosis and management. Gastroenterol Int. 1991;4:145-60.
4. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut. 1999;45 Suppl 2:II37-42.
5. Hongo M, Harasawa S, Mine T, Sasaki I, Matsueda K, Kusano M, et al. Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J Gastroenterol Hepatol. 2012; 27:62-8.
6. Miwa H. Life style in persons with functional gastrointestinal disorders - large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil. 2012;24(464-71):e217.
7. Kinoshita Y, Chiba T, Greup FS. Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: based on the large-scale survey, FUTURE study. Intern Med. 2011;50:2269-76.
8. McColl KE. Role of gastric acid in the aetiology of dyspeptic disease and dyspepsia. Baillieres Clin Gastroenterol. 1998;12: 489-502.
9. Thumshirn M. Pathophysiology of functional dyspepsia. Gut. 2002;51(Suppl 1):i63-6.
10. Miwa H, Watari J, Fukui H, Oshima T, Tomita T, Sakurai J, et al. Current understanding of pathogenesis of functional dyspepsia. J Gastroenterol Hepatol. 2011;26(Suppl 3):53-60.
11. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115:1346-52.
12. Tack J. Functional dyspepsia: impaired fundic accommodation. Curr Treat Options Gastroenterol. 2000;3:287-94.
13. Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106:508-14 (quiz 15).
14. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology. 2004;127:1239-55.
15. Waldron B, Cullen PT, Kumar R, Smith D, Jankowski J, Hopwood D, et al. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut. 1991;32:246-51.
16. Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci. 1998;43:2028-33.
17. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005;128:771-8.
18. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut. 1973;14:125-32.
19. Lemann M, Dederding JP, Flourie B, Franchisseur C, Rambaud JC, Jian R. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome. Dig Dis Sci. 1991;36:1249-54.
20. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology. 2001;121:526-35.
21. Samsom M, Verhagen MA, van Berge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 1999;116:515-20.
22. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut. 2008;57:674-83.
23. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol. 2005;100:1477-88.
24. Sakurai K, Nagahara A, Inoue K, Akiyama J, Mabe K, Suzuki J, et al. Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS). BMC Gastroenterol. 2012;12:42.
25. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007;5:178-85 (quiz 40).
26. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med. 2004;116:740-8.
27. Miwa H, Nakajima K, Yamaguchi K, Fujimoto K, Veldhuyzen van Zanten SJ, Kinoshita Y, et al. Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects. Aliment Pharmacol Ther. 2007;26:257-64.
28. Ishii M, Manabe N, Kusunoki H, Kamada T, Sato M, Imamura H, et al. Real-time evaluation of dyspeptic symptoms and gastric motility induced by duodenal acidification using noninvasive transnasal endoscopy. J Gastroenterol. 2008;43:935-41.
29. Lee KJ, Demarchi B, Demedts I, Sifrim D, Raeymaekers P, Tack J. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 2004;99:1765-73.
30. Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim D, Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut. 2005;54:1370-6.
31. di Stefano M, Vos R, Vanuytsel T, Janssens J, Tack J. Prolonged duodenal acid perfusion and dyspeptic symptom occurrence in healthy volunteers. Neurogastroenterol Motil. 2009;21:712-e40.
32. Hobson AR, Khan RW, Sarkar S, Furlong PL, Aziz Q. Development of esophageal hypersensitivity following experimental duodenal acidification. Am J Gastroenterol. 2004;99:813-20.
33. Lee KJ, Kim JH, Cho SW. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification. J Gastroenterol Hepatol. 2006;21:515-20.
34. van den Elzen BD, Tytgat GN, Boeckxstaens GE. Gastric hypersensitivity induced by oesophageal acid infusion in healthy volunteers. Neurogastroenterol Motil. 2009;21:160-9.
35. Lee KJ, Vos R, Janssens J, Tack J. Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol. 2004;286: G278-84.
36. Oshima T, Okugawa T, Tomita T, Sakurai J, Toyoshima F, Watari J, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. Aliment Pharmacol Ther. 2012;35: 175-82.
37. Blum AL, Talley NJ, O'Morain C, van Zanten SV, Labenz J, Stolte M, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med. 1998;339:1875-81.
38. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339:1869-74.
39. Miwa H, Hirai S, Nagahara A, Murai T, Nishira T, Kikuchi S, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients - a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2000;14: 317-24.
40. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ. 2000;321:659-64.
41. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter. 2007;12:541-6.
42. Sugano K. Should we still subcategorize Helicobacter pyloriassociated dyspepsia as functional disease? J Neurogastroenterol Motil. 2011;17:366-71.
43. Suzuki H, Nishizawa T, Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol. 2011;26(Suppl 3):42-5.
44. Aro P, Talley NJ, Ronkainen J, Storskrubb T, Vieth M, Johansson SE, et al. Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population- based study. Gastroenterology. 2009;137:94-100.
45. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med. 2003;65:528-33.
46. Kaneko H, Mitsuma T, Fujii S, Uchida K, Kotera H, Furusawa A, et al. Immunoreactive-somatostatin concentrations of the human stomach and mood state in patients with functional dyspepsia: a preliminary case-control study. J Gastroenterol Hepatol. 1993;8:322-7.
47. Talley NJ, Locke GR, Lahr BD, Zinsmeister AR, Cohard-Radice M, D'Elia TV, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther. 2006;23: 923-36.
48. Miller V, Whorwell PJ. Hypnotherapy for functional gastrointestinal disorders: a review. Int J Clin Exp Hypn. 2009;57: 279-92.
49. Geeraerts B, Vandenberghe J, Van Oudenhove L, Gregory LJ, Aziz Q, Dupont P, et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology. 2005;129:1437-44.
50. Fass R, Naliboff BD, Fass SS, Peleg N, Wendel C, Malagon IB, et al. The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. Gastroenterology. 2008;134:696-705.
51. Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol. 2012;107:657-66.
52. Pilichiewicz AN, Feltrin KL, Horowitz M, Holtmann G, Wishart JM, Jones KL, et al. Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol. 2008;103:2613-23.
53. Pilichiewicz AN, Horowitz M, Holtmann GJ, Talley NJ, Feinle-Bisset C. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2009;7:317-22.
54. Kusano M, Zai H, Hosaka H, Shimoyama Y, Nagoshi A, Maeda M, et al. New frontiers in gut nutrient sensor research: monosodium L-glutamate added to a high-energy, high-protein liquid diet promotes gastric emptying: a possible therapy for patients with functional dyspepsia. J Pharmacol Sci. 2010;112:33-6.
55. Gonlachanvit S. Are rice and spicy diet good for functional gastrointestinal disorders? J Neurogastroenterol Motil. 2010;16: 131-8.
56. David D, Mertz H, Fefer L, Sytnik B, Raeen H, Niazi N, et al. Sleep and duodenal motor activity in patients with severe nonulcer dyspepsia. Gut. 1994;35:916-25.
57. Lacy BE, Everhart K, Crowell MD. Functional dyspepsia is associated with sleep disorders. Clin Gastroenterol Hepatol. 2011;9:410-4.
58. Delvaux M, Denis P, Allemand H. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. French Club of Digestive Motility. Eur J Gastroenterol Hepatol. 1997;9:345-52.
59. Bradford K, Shih W, Videlock EJ, Presson AP, Naliboff BD, Mayer EA, et al. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol. 2012;10(385-90):e1-3.
60. Klooker TK, Braak B, Painter RC, de Rooij SR, van Elburg RM, van den Wijngaard RM, et al. Exposure to severe wartime conditions in early life is associated with an increased risk of irritable bowel syndrome: a population-based cohort study. Am J Gastroenterol. 2009;104:2250-6.
61. Ren TH, Wu J, Yew D, Ziea E, Lao L, Leung WK, et al. Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2007;292: G849-56.
62. Barreau F, Ferrier L, Fioramonti J, Bueno L. New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models. Pediatr Res. 2007;62:240-5.
63. Dunphy RC, Bridgewater L, Price DD, Robinson ME, Zeilman CJ 3rd, Verne GN. Visceral and cutaneous hypersensitivity in Persian Gulf war veterans with chronic gastrointestinal symptoms. Pain. 2003;102:79-85.
64. Wilpart K, Törnblom H, Svedlund J, Tack J, Simren M, Van Oudenhove L. The role of coping resources in irritable bowel syndrome: relationship with gastrointestinal symptom severity and somatization. Gastroenterology. 2012;142:S299-300.
65. Geeraerts B, Van Oudenhove L, Fischler B, Vandenberghe J, Caenepeel P, Janssens J, et al. Influence of abuse history on gastric sensorimotor function in functional dyspepsia. Neurogastroenterol Motil. 2009;21:33-41.
66. Brevet M, Kojima H, Asakawa A, Atsuchi K, Ushikai M, Ataka K, et al. Chronic foot-shock stress potentiates the influx of bone marrow-derived microglia into hippocampus. J Neurosci Res. 2010;88:1890-7.
67. Holtmann G, Siffert W, Haag S, Mueller N, Langkafel M, Senf W, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology. 2004;126:971-9.
68. Oshima T, Nakajima S, Yokoyama T, Toyoshima F, Sakurai J, Tanaka J, et al. The G-protein beta3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med Genet. 2010;11:13.
69. Tahara T, Arisawa T, Shibata T, Wang F, Nakamura M, Sakata M, et al. Homozygous 825T allele of the GNB3 protein influences the susceptibility of Japanese to dyspepsia. Dig Dis Sci. 2008;53:642-6.
70. Toyoshima F, Oshima T, Nakajima S, Sakurai J, Tanaka J, Tomita T, et al. Serotonin transporter gene polymorphism may be associated with functional dyspepsia in a Japanese population. BMC Med Genet. 2011;12:88.
71. Oshima T, Toyoshima F, Nakajima S, Fukui H, Watari J, Miwa H. Genetic factors for functional dyspepsia. J Gastroenterol Hepatol. 2011;26(Suppl 3):83-7.
72. Tack J, Demedts I, Dehondt G, Caenepeel P, Fischler B, Zandecki M, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology. 2002;122: 1738-47.
73. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology. 2005;129:98-104.
74. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20(Suppl 2): 1-9.
75. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52:523-6.
76. Futagami S, Shindo T, Kawagoe T, Horie A, Shimpuku M, Gudis K, et al. Migration of eosinophils and CCR2-/CD68- double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010; 105:1835-42.
77. Vanheel H, Vanuytsel T, Holvoet L, Pardon N, Vicario M, Kindt S, et al. A pilot study on duodenal mucosal integrity in functional dyspepsia. Gastroenterology. 2011;140:S-169.
78. Holtmann G, Gapasin J. Failed therapy and directions for the future in dyspepsia. Dig Dis. 2008;26:218-24.
79. Haag S, Senf W, Tagay S, Langkafel M, Braun-Lang U, Pietsch A, et al. Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy? Aliment Pharmacol Ther. 2007;25:973-86.
80. Haug TT, Wilhelmsen I, Svebak S, Berstad A, Ursin H. Psychotherapy in functional dyspepsia. J Psychosom Res. 1994;38:735-44.
81. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology. 2002;123:1778-85.
82. Talley NJ, Vakil N, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol. 2005;100:2324-37.
83. Miwa H, Ghoshal UC, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil. 2012;18:150-68.
84. Kato M, Watanabe M, Konishi S, Kudo M, Konno J, Meguro T, et al. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther. 2005;21(Suppl 2):27-31.
85. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2003;1:CD001960.
86. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;4:CD001960.
87. Wong WM, Wong BC, Hung WK, Yee YK, Yip AW, Szeto ML, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut. 2002;51:502-6.
88. Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol. 2007;22:304-10.
89. Talley NJ. Therapeutic options in nonulcer dyspepsia. J Clin Gastroenterol. 2001;32:286-93.
90. Tack J, Masclee A, Heading R, Berstad A, Piessevaux H, Popiela T, et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009;21:272-80.
91. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebocontrolled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61:821-8.
92. Kusunoki H, Haruma K, Manabe N, Imamura H, Kamada T, Shiotani A, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24:540-e251.
93. Seto K, Sasaki T, Katsunuma K, Kobayashi N, Tanaka K, Tack J. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008;20: 1051-9.
94. Hojo M, Miwa H, Yokoyama T, Ohkusa T, Nagahara A, Kawabe M, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol. 2005;40:1036-42.
95. Miwa H, Nagahara A, Tominaga K, Yokoyama T, Sawada Y, Inoue K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009;104:2779-87.
96. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108:65-72.
97. Tatsuta M, Iishi H, Nakaizumi A, Okuda S. Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharmacol Ther. 1992;6:221-8.
98. Hayakawa T, Arakawa T, Kase Y, Akiyama S, Ishige A, Takeda S, et al. Liu-Jun-Zi-Tang, a kampo medicine, promotes adaptive relaxation in isolated guinea pig stomachs. Drugs Exp Clin Res. 1999;25:211-8.
99. Arai M, Matsumura T, Tsuchiya N, Sadakane C, Inami R, Suzuki T, et al. Rikkunshito improves the symptoms in patients with functional dyspepsia, accompanied by an increase in the level of plasma ghrelin. Hepatogastroenterology. 2012;59:62-6.
100. Miwa H, Osada T, Nagahara A, Ohkusa T, Hojo M, Tomita T, et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol. 2006;21:1826-31.